105 related articles for article (PubMed ID: 5067490)
21. [Effect of BAY a 1040 on renal function in hypertension].
Klütsch K; Schmidt P; Grosswendt J
Arzneimittelforschung; 1972 Feb; 22(2):377-80. PubMed ID: 5067491
[No Abstract] [Full Text] [Related]
22. [Therapy of ischemic heart diseases with carbochromen].
Savenkov PM; Arsukuni RO; Pflug C
Arzneimittelforschung; 1970 Mar; 20():461-2. PubMed ID: 5468731
[No Abstract] [Full Text] [Related]
23. [The mechanism of coronary dilatating action of nifedipine].
Kosche F; Raff WK; Lochner W
Arzneimittelforschung; 1972 Jan; 22(1):39-42. PubMed ID: 5066996
[No Abstract] [Full Text] [Related]
24. Inotropic effects of Nifedipine: a new coronary dilating agent.
Strauer BE
Int J Clin Pharmacol; 1974 Mar; 9(2):101-7. PubMed ID: 4827553
[No Abstract] [Full Text] [Related]
25. The effects of a new coronary vasocilator (BAY-a-1040, Nifedipine) on the coronary and systemic haemodynamics in the anaesthetized dog.
Maxwell GM; Rencis V
Aust J Exp Biol Med Sci; 1973 Feb; 51(1):117-20. PubMed ID: 4699546
[No Abstract] [Full Text] [Related]
26. [Electromechanical uncoupling of vascular smooth muscle as the basic principle of coronary dilatation by 4-(2'-nitrophenyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (BAY a 1040, Nifedipine). 1. The significance of Ca ++ ions for the bioelectrical and mechanical activity of smooth muscle].
Grün G; Fleckenstein A
Arzneimittelforschung; 1972 Feb; 22(2):334-44. PubMed ID: 4623697
[No Abstract] [Full Text] [Related]
27. [Effects of octapressin on the general and coronary circulation in anesthetized, closed chest dogs].
Strauer BE; Reploh HD; Cott L; Tauchert M; Bretschneider HJ
Arztl Forsch; 1969 Jul; 23(7):227-35. PubMed ID: 5820305
[No Abstract] [Full Text] [Related]
28. Hemodynamic effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155) at rest and during exercise with special respect to the pulmonary circulation.
Koch G
Arzneimittelforschung; 1971 Jan; 21(1):57-61. PubMed ID: 5108382
[No Abstract] [Full Text] [Related]
29. Systemic and coronary hemodynamic effects of 3-(beta-diethylamino-ethyl)-4-methyl-7-carbethoxy-methoxy-2-oxo-(1,2-chromene)-hydrochloride (Intensain, A-27053).
Rowe GG; McKenna DH; Sialer S; Corliss RJ
Vasc Dis; 1967 Jun; 4(3):183-90. PubMed ID: 6028828
[No Abstract] [Full Text] [Related]
30. Hemodynamic effects of the new vasodilator drug Bay k 5552 in man.
Vogt A; Neuhaus KL; Kreuzer H
Arzneimittelforschung; 1980; 30(12):2162-4. PubMed ID: 7194078
[TBL] [Abstract][Full Text] [Related]
31. [Development of coronary collaterals following oral long-term therapy with nifedipine. Increased survival time following experimental coronary occlusion].
van Ackern K; Braasch W; Brückner UB; Heger W; Schmier J
Arzneimittelforschung; 1974 Oct; 24(10):1577-81. PubMed ID: 4479765
[No Abstract] [Full Text] [Related]
32. Haemodynamic effects of vasoactive agents following chronic state of high cardiac output in anaesthetized rats.
Guo L; Tabrizchi R
Eur J Pharmacol; 2008 May; 586(1-3):266-74. PubMed ID: 18367170
[TBL] [Abstract][Full Text] [Related]
33. Effects of various coronary vasodilators on myocardial oxygen consumption.
Oguro K; Kubota K; Kimura T; Hashimoto K
Jpn J Pharmacol; 1973 Aug; 23(4):459-66. PubMed ID: 4202125
[No Abstract] [Full Text] [Related]
34. Effects of selective coronary hypotension and nitroglycerin or Bay a 1040 on the distribution of Rb86 clearance in the canine heart.
Nakamura M; Eto Y; Hamanaka N; Kuroiwa A; Tomoike H
Cardiovasc Res; 1973 Nov; 7(6):777-88. PubMed ID: 4206541
[No Abstract] [Full Text] [Related]
35. Regional blood flow and cardiac responses to hydralazine.
Spokas EG; Wang HH
J Pharmacol Exp Ther; 1980 Feb; 212(2):294-303. PubMed ID: 7351643
[No Abstract] [Full Text] [Related]
36. Cardiovascular effects of beta blockade with inderal in normal subjects.
Gebhardt W; König K; Büchner C
Int Z Klin Pharmakol Ther Toxikol; 1968 Apr; 1(4):289-95. PubMed ID: 4882204
[No Abstract] [Full Text] [Related]
37. [Promotion of organ circulation by raubasine].
Dietmann K
Arzneimittelforschung; 1967 Aug; 17(8):969-75. PubMed ID: 5632071
[No Abstract] [Full Text] [Related]
38. The clinical effect of 4-(2'-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine (BAY a 1040) on angina pectoris evaluated by sequential analysis.
Kimura E; Mabuchi G; Kikuchi H
Arzneimittelforschung; 1972 Feb; 22(2):365-7. PubMed ID: 4623700
[No Abstract] [Full Text] [Related]
39. Clinical experience with a new coronary-active substance (BAY 1 1040).
Kobayashi T; Ito Y; Tawara I
Arzneimittelforschung; 1972 Feb; 22(2):380-9. PubMed ID: 5067492
[No Abstract] [Full Text] [Related]
40. Vasodilator profile of a new 1,4-dihydropyridine derivative, 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)]-ethyl ester 5-methyl ester hydrochloride (YC-93).
Takenaka T; Usuda S; Nomura T; Maeno H; Sado T
Arzneimittelforschung; 1976; 26(12):2172-8. PubMed ID: 1037267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
